ESMO Magnitude of Clinical Benefit Scale

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

The European Society for Medical Oncology (ESMO) has developed a validated and reproducible scale, the ESMO-MCBS to assess the magnitude of clinical benefit for cancer medicines.

This scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from a new anti-cancer treatment.

The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost effective and affordable cancer care.

The ESMO-MCBS will be a dynamic tool and its criteria will be revised on a regular basis.

Fortunato Ciardiello, Elisabeth de Vries, Josep Tabernero and Alexandru Eniu introduce The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) – a standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies.